The substantial number of antibacterial agents developed during the second half of the last century appeared so successful in combating common pathogens, that bacterial infections were considered to be overcome. However the past two decades have shown the celebrations to be premature. Especially in a hospital setting, resistance to several of the most efficacious antibacterial agents has been rising constantly. Both Gram-positive and Gram-negative pathogens have collected a vast array of resistance mechanisms. Treatment failure due to antibiotic resistance is particularly grave for patients whose immune system is compromised, such as people with an underlying disease and patients in intensive care units. According to recent health statistics, each year about 2 million people acquire bacterial infections in U.S. hospitals alone, of which 90,000 die as a result. About 70 percent of these infections were caused by bacteria resistant to at least one drug.
AiCuris' mission is the development of life-saving cures for the treatment of severe Gram-positive and Gram-negative infections to ensure effective antibacterial therapeutic options for the future. The company’s highly innovative antibacterial pipeline comprises several discovery programs as well as late stage preclinical candidates targeting multi-resistant pathogens.